iflybuds
Seed Round in 2025
Vision Intelligence is a AI smart hardware company that manufactures and sells interactive intelligence based electronic consumer products.
Zhihang Zhong is a prominent researcher in the field of artificial intelligence, particularly known for his work on integrating spatial perception and reasoning into AI systems.
Force Inspiration
Angel Round in 2025
Force Inspiration is a start-up focusing on embodied intelligence technology. The company mainly engages in technology development, technical consulting, software development, basic artificial intelligence software development, information system integration services, intelligent robot research and development and sales, and industrial robot manufacturing and sales.
Eco Polymer
Series B in 2025
Eco Polymer focuses on research and production of medical catheters and membrane materials for various applications in the medical device industry.
Weimei Health
Series A in 2025
Weimei Health is a provider of smart solutions for medical information technology
Singular Medical
Series C in 2025
Singular Medical is a technology company focused on the research and development of cardiac rhythm management (CRM) products. It specializes in designing and industrializing a comprehensive range of high-quality medical devices, including implantable cardioverter defibrillators, pacemakers, and implantable cardiac monitors. By creating a complete technical platform, Singular Medical offers solutions that encompass the entire patient journey, from initial detection of cardiac issues to ongoing follow-up care. The company's commitment to providing reliable and professional medical equipment aims to enhance the quality of care for patients with various cardiac conditions.
TOPI Imaging Technology
Series E in 2025
TOPI Imaging Technology is a medical device firm providing OCT retinal diagnostic system and sweep optical biometer.
Pulnovo Medical
Series C in 2025
Pulnovo Medical, established in 2013 in Wuxi, Anhui, is focused on the development, production, and service provision of innovative medical technologies. The company specializes in creating advanced equipment for treating pulmonary hypertension, particularly through the use of pulse radiofrequency ablation technology. Its core products include pioneering high-frequency ablation equipment and intravascular catheters, which are protected by global invention patents. Pulnovo Medical aims to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure by offering cutting-edge treatment solutions.
Video Rebirth
Angel Round in 2025
Video Rebirth Limited is a private limited company that is established with shares.
DH-Robotics
Venture Round in 2025
DH Robotics Technology Co., Ltd., founded in 2016 and based in China, specializes in the research and development of robotic hands and industrial robots. The company focuses on creating electric gripping jaws intended to enhance intelligent manufacturing processes. Its products are designed to be stable, secure, and easily integrated, catering to the needs of advanced manufacturing and lean production. By developing cost-effective solutions, DH Robotics aims to support flexible and intelligent demands within the manufacturing sector.
Nanos Medical
Venture Round in 2025
Nanos Medical specializes in the research, development, manufacturing, and sales of disposable medical devices, primarily targeting the cardiovascular and ear, nose, and throat (ENT) fields. The company offers a range of innovative products, including sinus balloon catheters, eustachian tube balloons, disposable nasopharyngeal airways, nasolacrimal balloons, and drug-eluting stents for sinus applications. Through its advanced medical devices, Nanos Medical aims to enhance treatment options for hospitals and patients, contributing to improved healthcare outcomes.
Vivatides Therapeutics
Series C in 2025
Vivatides Therapeutics develops new RNA treatments to help improve patients' lives using biotechnology research.
Stairway Medical
Series B in 2025
Stairway Medical is a ladder of human progress and evolution stairs up for human health. The technology and products will be applicable to medical scenarios such as human function restoration, disease treatment, and functional enhancement, as well as related scientific research work.
Makera
Angel Round in 2025
Makera is essentially creating a maker's dream CNC machine; we use it every day for various projects and enjoy the experience, and we hope you will too.
Auron Therapeutics
Series B in 2025
Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.
Baoling Bio
Series B in 2025
Baoling Bio is an innovative drug research and development and industrialization service provider. The company's research and development pipeline covers the research and development of innovative drugs such as tumors (solid tumors and hematomas), autoimmune diseases, and cytokine storms caused by new coronavirus pneumonia.
MiGuo AI
Angel Round in 2025
Miguo AI enhances artificial intelligence in various industries and transforms visual content creation.
Xi'an Dunbo Medical Equipment
Series A in 2025
Xi'an Dunbo Medical Equipment focuses on the research, development, and production of AI medical devices. The products currently under development are cardiac pacemakers and brain pacemakers, Cardiac defibrillators. Self-developed products include chips, hardware circuits, software application systems, and structural materials.
Xinzeyuan
Series B in 2025
Xinzeyuan Medical specializes in the manufacturing of critical precision components and disposable medical endoscopes, serving primarily hospital clients. Their product portfolio includes minimally invasive surgical instruments and other medical consumables, aiming to enhance safety and efficiency in surgical procedures for healthcare professionals.
Iongen Therepeutics
Seed Round in 2025
Iongen Therepeutics is an innovative drug research and development company focusing on pain treatment.
Umoja Biopharma
Series C in 2025
Umoja Biopharma is a biotechnology company specializing in innovative immunotherapy aimed at transforming cancer treatment. The company focuses on reprogramming T cells to effectively target cancer within patients' bodies, enhancing the immune response to combat both solid tumors and hematological cancers, which often show poor responses to conventional therapies. Umoja Biopharma's proprietary CAR T-cell gene therapy platform is designed to deliver scalable therapeutic regimens, allowing for tailored treatment options that can be administered to any patient, regardless of tumor type or stage. This approach aims to improve patient outcomes and quality of life by providing a safe and controllable method to attack cancer directly.
Cornerstone Robotics
Series C in 2025
Cornerstone Robotics develops medical robotic devices designed for precise surgical robotic systems. Their products feature multi-degree-of-freedom robotic arms, real-time imaging integration, and intuitive surgeon interfaces, enabling healthcare providers to perform advanced minimally invasive surgeries with greater control and consistency.
Windward Bio
Series A in 2025
Windward Bio is a clinical-stage biopharmaceutical company dedicated to enhancing outcomes for patients with advanced immunological diseases, focusing on severe respiratory conditions. The company is advancing a fully human monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 clinical trials. This antibody, administered subcutaneously, potently binds to the TSLP ligand, extending its half-life and silencing its effector functions. Windward Bio is also developing innovative bispecific programs for other immunological disorders, led by a team of experienced biopharmaceutical executives aiming to address significant unmet medical needs in this field.
Leyden Labs
Series B in 2025
Leyden Labs develops a Mucosal Protection Platform to protect against respiratory viruses, including influenza and coronaviruses. The company offers a portfolio of broad protective nasal sprays designed to reduce the risk of infection and limit transmission, aiming to improve public health through innovative protection methods. Its team combines biotechnology veterans with new talent to advance solutions that address common viral threats at the mucosal surface.
AusperBio
Series B in 2024
AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, AusperBio aims to deliver effective targeted therapies that leverage antisense oligonucleotide technology. The company is dedicated to transforming the treatment landscape for hepatitis B, with an emphasis on finding a cure and providing protection through novel therapeutic approaches. Additionally, AusperBio's research extends to addressing a variety of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, thereby broadening the potential impact of its therapeutic innovations.
The goal of Stepstar is to "Ten Times the Possibility of Everyone" through Intelligent Step. Step Star firmly creates its own super model and actively uses important resources like
Zhipu AI
Venture Round in 2024
Zhipu AI is a technology company specializing in developing large-scale artificial intelligence models. It offers API services powered by its General Language Model (GLM) series, designed to handle both Chinese and English tasks. The company's products include chatbots and advanced AI tools, aiming to reduce manual labor in digital tasks.
Tenpoint Therapeutics
Venture Round in 2024
Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.
Soda Health
Series B in 2024
Founded in 2021, Soda Health is a Chicago-based healthcare technology company committed to reducing health disparities by addressing social determinants of health. It operates a platform that delivers personalized benefits, providing real-time access to essential services such as healthy food, over-the-counter medications, and transportation.
BioHeng is a clinical biopharmaceutical and biotechnology Company focuses on novel immunotherapy and next-generation gene therapy development for treating cancers and various diseases. Founded in 2017, Bioheng has established a high standard GMP grade clinical translational center, and is leading in the field of cell engineering, proliferation and clinical applications. Particularly, Bioheng owns several cutting-edge patents plus extensive industry experience, and has built a complete, closed and automated production system in compliance with regulatory guidelines.
In 2018, Bioheng has successfully raised tens of millions of RMB seeding fund from Simcere Pharmaceutical Group, aiming to accelerate the development of immunotherapy via integrating resources from both parties. Bioheng is dedicated to develop safer, effective and less expensive cell therapy drugs to benefit more patients.
iMile specializes in logistics and courier services across the Middle East. It caters primarily to e-commerce businesses, offering innovative solutions such as Cash on Delivery with tracking, real-time online tracking, international transport, overseas warehousing, and last-mile delivery.
Tupos Therapeutics
Seed Round in 2024
The company is currently operating in Stealth Mode.
Duet is a dating application helps you find meaningful relationships based on shared interests and experiences.
Dearer Medical
Venture Round in 2024
Dearer Medical is a medical device company based in China that specializes in the development, production, and sales of eye-related products, particularly contact lenses. The company is dedicated to research and development in this field, focusing on both practical and fashionable color contact lens options. By combining innovation with quality manufacturing, Dearer Medical aims to meet the diverse needs of customers seeking enhanced vision solutions.
Tianhu Technology
Series A in 2024
Tianhu Technology provides drug research and development services through independent collaborative closed-loop iterations, deeply integrating AI solutions with the drug development and production process. Tianhu Technology is an innovative drug R&D company that offers high-throughput phenotypic screening and physical computing technology, as well as AI solutions that are deeply integrated into the drug R&D process.
Matwings Technology
Series A in 2024
Matwings is a biotechnology company that employs artificial intelligence to design optimized proteins. It collaborates with major pharmaceutical firms to develop innovative drugs targeting challenging targets.
Bioyond Tech
Series A in 2024
Bioyond Tech utilizes robotics and artificial intelligence technology to provide a new generation of modular products and automation solutions for the life sciences sector.
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.
XellSmart
Series B in 2024
XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.
LaNova Medicines
Series C in 2024
LaNova Medicines is a clinical-stage pharmaceutical company specializing in innovative drug research and development, focusing on unmet therapeutic needs in tumor immunity and tumor microenvironment. The company aims to develop 'world's first' and 'best-in-class' potential bio-innovative drugs.
Tachem is a biotechnology company that develops, produces, and distributes a range of products derived from the protected amino acid series. These products cater to diverse industries, including medical, healthcare, food, and cosmetics, among others. Tachem's primary offerings comprise protective amino acids, non-natural amino acids, and high-quality chemical raw materials, serving as biotechnical solutions for various industrial users.
Bytelumio
Series A in 2024
Bytelumio creates advanced all-optical networks that deliver high-speed connections of 800G and 1.6T for data centers.
Original Point
Series C in 2024
Original Point focuses on the development of CNC systems with five-axis and multi-axis linkage capabilities.
Hope Medicine
Series B in 2024
Hope Medicine is a biopharmaceutical company focused on researching, developing, and commercializing innovative drugs to enhance the quality of life for various common male and female diseases. The company specializes in translational medicine and aims to address significant health challenges by leveraging global research initiatives. Hope Medicine is engaged in the development of monoclonal antibodies, protein-based therapies, and other drug formulations targeting endocrine, cardiovascular, and metabolic diseases. Through its efforts, the company seeks to provide underserved patient populations with access to effective and affordable treatments, ultimately improving their health outcomes.
LongBio Pharma
Series B in 2024
LongBio Pharma is a biotechnology company focused on developing antibody-based biologics for autoimmune and allergic diseases. Its platform concentrates on complement and IgE pathways, aiming to provide affordable, high-quality treatments that enhance patients' access to more effective therapies.
Candid Therapeutics
Series A in 2024
Candid Therapeutics is a biotechnology company specializing in the development of innovative therapies for immunological disorders. The company's primary focus is on creating novel, user-friendly treatments for autoimmune diseases. Their core technology involves advanced T-cell engager antibodies, which precisely redirect T-cells to selectively eliminate autoreactive B-cells, aiming to deliver transformative efficacy and improved therapeutic outcomes for patients.
Epigenic Therapeutics
Series A in 2024
Epigenic Therapeutics is a biotechnology company focused on developing gene editing therapies that leverage gene-silencing technology to address a range of diseases. The firm specializes in epigenome editing, aiming to regulate various conditions, including those related to ophthalmology, neurodegeneration, metabolism, and rare diseases. By creating innovative treatments, Epigenic Therapeutics seeks to offer effective solutions for patients suffering from chronic and severe health issues.
Zhipu AI is a technology company specializing in developing large-scale artificial intelligence models. It offers API services powered by its General Language Model (GLM) series, designed to handle both Chinese and English tasks. The company's products include chatbots and advanced AI tools, aiming to reduce manual labor in digital tasks.
Infinigence
Series A in 2024
Infinigence is dedicated to providing AGI computing power solutions based on its large model energy efficiency optimization tools, with the goal of resolving the challenge of efficient and unified deployment of large model algorithms to large computing power chips.
Mufan Power
Series B in 2024
Mufan Power is a new energy high-tech enterprise specializing in turbomachinery. It develops a new generation of zero-carbon hydrogen power generation technologies and products, with hydrogen gas turbines as its core offering. These turbines are intended for distributed energy and data centers, rail transit, ship power, vehicle power, and energy storage peak shaving, supporting carbon-neutral applications across multiple sectors.
SPEEDIANCE
Series B in 2024
Speediance designs and operates smart at-home fitness equipment for strength training and provides an online platform with training guidance and strength-training courses, connecting individual users with a workout community and resources to improve home workouts.
Pelliot is an outdoor sports brand that designs and manufactures high-performance clothing for outdoor enthusiasts. The company specializes in innovative design and research & development, offering a range of products including performance, mountain, classic, and training wear. Pelliot's commitment lies in producing professional-grade outdoor sports products, supporting outdoor lovers with reliable equipment.
Guangjing Energy
Series A in 2024
Guangjing Energy specializes in the R&D and mass production of durable, large-area perovskite solar cell modules. They develops perovskite film printing technology with independent intellectual property rights and realized the preparation of large-area perovskite components.
Zhongyi Rehabilitation
Seed Round in 2024
Zhongyi Rehabilitation is a provider of rehabilitation products and services that focuses on the operation of chain rehabilitation centers to provide patients with one-stop professional rehabilitation needs and solutions.
TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution.
FXiaoKe
Venture Round in 2024
FXiaoKe is a Beijing-based company founded in December 2011 that specializes in developing a cloud-based sales management platform tailored for Chinese enterprises. The platform incorporates features of dynamic customer relationship management (CRM) and integrates seamlessly with enterprise WeChat, facilitating efficient collaboration among businesses, individuals, and systems. FXiaoKe’s software solutions support various management functions, including field operation management, distribution chain management, and customer relationship management, specifically targeting small and medium-sized enterprises. The platform is designed to enhance productivity by enabling users to manage sales through social interaction tools and offers online office automation services that facilitate information sharing between personal computers and smartphones. The company's focus encompasses a customer-centric approach with industry-specific strategies aimed at fostering growth in sectors such as high-tech, modern corporate services, fast-moving consumer goods, agriculture, and large-scale manufacturing.
SinoUnited Health
Series D in 2024
SinoUnited Health is a medical center based in Shanghai, China, specializing in sports medicine, physical therapy, pain management, orthopedics, and neurology services. Established in 2004, the center offers a wide range of treatments, including services for foot and ankle issues, acupuncture, chronic pain, movement disorders, migraines, tremors, electromyography, balance training, home exercise programs, manual therapy, post-stroke care, post-herpetic neuralgia, osteoarthritis, and carpal tunnel syndrome. Known for its commitment to high-quality patient care, SinoUnited Health integrates thoughtful design with international standards to enhance the patient experience. The center has built a strong reputation for delivering reliable diagnoses and effective treatment outcomes, ensuring high levels of customer satisfaction among both local residents and visitors.
Chenzhang Biotechnology
Seed Round in 2024
Chenzhang Bio is a biotechnology developer specializing in stem cell storage and treatment technology. focusing on stem cell storage and treatment technologies, company's research and commercialization, enhancing its R&D team and promoting clinical application of stem cell treatment technology
Dr.Clear Aligner
Series A in 2024
Dr.Clear is an oral invisible orthodontic solution service provider that specializes in offering safe and comfortable digital solutions for face development management and invisible dental correction for children and adolescents.
CSR Biotech
Series A in 2024
CSR Biotech is a biological research company that specializes in the development and manufacturing of super-resolution imaging instruments for living cells. The company focuses on creating and deploying advanced imaging technology, offering a range of services including customized cell sample generation, high-throughput detection, imaging studies, and image post-processing with quantitative analysis. By providing these specialized tools and services, CSR Biotech aims to support bio researchers in discovering new disease biomarkers and innovative drug targets, thereby contributing to advancements in the field of biotechnology.
Outpace Bio
Series B in 2024
Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
LTZ Therapeutics
Series A in 2024
LTZ Therapeutics specializes in the development of innovative immunotherapies aimed at treating patients with cancer and other diseases that currently lack effective treatment options. By employing reverse translational science and tumor biology in conjunction with machine learning, the company focuses on creating novel cancer therapies. This approach enables the identification and development of targeted treatments that address unmet clinical needs, ultimately improving patient outcomes in the field of oncology and beyond.
Founded in 2018, Engitist specializes in researching, manufacturing, and selling high-precision optical measurement and testing equipment for the semiconductor industry. Based in Suzhou, China, the company offers products such as microscopic film measurement, optical defect detection, and optical linewidth measurement equipment, serving customers globally.
SonoSilicon
Angel Round in 2024
SonoSilicon researches on medical-grade micro-on-chip ultrasound systems and chip design and promotes the medical device industry.
LaNova Medicines
Series C in 2024
LaNova Medicines is a clinical-stage pharmaceutical company specializing in innovative drug research and development, focusing on unmet therapeutic needs in tumor immunity and tumor microenvironment. The company aims to develop 'world's first' and 'best-in-class' potential bio-innovative drugs.
Alpha Biopharma
Series B in 2024
Alpha Biopharma Inc. is a biopharmaceutical company based in Huangpu, China, focused on researching and developing innovative therapeutics. The company is primarily engaged in the clinical development of AZD3759, a small molecule tyrosine kinase inhibitor designed to treat patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) who have central nervous system metastases. Alpha Biopharma collaborates with prominent international pharmaceutical companies and utilizes a strong scientific consulting and management team to ensure rigorous research and development processes. The company emphasizes a multi-faceted approach to drug development, which includes research, market strategy, and intellectual property protection, while working closely with leading contract research organizations, contract manufacturing organizations, hospitals, and institutes to facilitate the orderly implementation of its projects.
DK Medtech
Series E in 2024
DK Medtech is a medical technology company based in Suzhou, China, specializing in the development and production of balloon catheter medical devices. Founded in 2015, the company has positioned itself as a leader in the medical device industry, focusing on innovative solutions to address complex healthcare challenges. Through its commitment to excellence, DK Medtech aims to improve patient outcomes and enhance the quality of healthcare.
Simaixu Biotechnology
Angel Round in 2024
Simaixu Biotechnology is a biopharmaceutical firm that develop small molecule drugs for cancer, and chronic diseases with new technologies
Novamab is a biotechnology company specializing in the development of novel nanobodies, a type of single-domain antibody with unique therapeutic advantages. With over 15 years of experience in nanobody research and development, the company's team of pioneers in this field has established platforms to maximize the potential of nanobodies. Novamab focuses on creating innovative drug formulations such as inhaled macromolecular drugs, albumin nanobody long-acting therapies, and nanobody double-antibody combinations. Their primary goal is to address unmet clinical needs by improving administration methods and reducing treatment cycles for major chronic diseases like cancer, autoimmune disorders, and cardiovascular conditions.
Thorough Future
Series A in 2024
Thorough Future specializes in integrating advanced technology into medical care. It focuses on enhancing diagnostic services' accuracy and efficiency for clinical medicine and providing personalized treatment recommendations, particularly for cancer patients.
Dezhen Technology
Series C in 2024
Dezhen Technology provides solutions for medical institutions to help hospitals develop clinical, and scientific research management.
Dezhen Technology is headquartered in Hongkou, China.
Horizone Technologies
Series A in 2024
Horizone Technologies is membrane materials and excellent filtration solutions manufacturer focusing on the R&D and production
Yanshengchao
Angel Round in 2024
Room A204-1, Floor 2, Building 2, Yard 9, Yike Road
Life Science Park, Changping District
Beijing
China
Shengshu Technology
Venture Round in 2024
Shengshu Technology specializes in developing generative AI infrastructure for multi-modal large-scale models. It integrates text, images, videos, 3D data, and other modalities to create innovative AI solutions.
Yidao Biotechnology
Series C in 2024
Yidao Biotechnology research and develops vaccines and biomedical products.
It focuses on the research and development of a variety of vaccines such as recombinant protein antigen vaccine, new virus vector vaccine, messenger RNA vaccine, and vaccine adjuvant platforms, providing vaccines to meet the needs of human health in both domestic and international markets.
The Suzhou, Jiangsu-based biotech company was established in 2017.
Brise Pharma
Seed Round in 2024
Brise Pharma is a scientific research company specializing in developing novel biopharmaceutical drugs for treating pain. Its primary focus lies in creating innovative and distinct analgesic treatments targeting migraine, neuropathic, and musculoskeletal pain, aiming to provide safe, effective, and accessible pain relief solutions globally.
GenEditBio
Seed Round in 2024
GenEditBio is a biotechnology company dedicated to developing curative gene editing therapies for genetic disorders. It focuses on innovative in vivo gene editing tools and delivery systems.
Jiakekangnuo Bio
Angel Round in 2024
Jiakekangnuo Bio focuse on technology, promote industrial incubation through strategic investment, and achieves commercialization.
CureGenetics
Series B in 2024
CureGenetics is a biotechnology company focused on advancing innovative medicines and molecular diagnostics through the application of gene editing technologies. The company specializes in the research and development of solutions aimed at the treatment of cancers and genetic diseases. CureGenetics is dedicated to creating next-generation therapies that enhance patient outcomes by leveraging cutting-edge techniques in gene editing and delivery platforms. Through its efforts, the company aims to contribute significantly to the field of personalized medicine and improve treatment options for complex health conditions.
Emulate is a biotechnology company that develops organ-on-a-chip human emulation technology to model how diseases, medicines, chemicals, and foods affect human health. Its platform includes lung, intestinal, liver, and skin organ chips that reproduce normal biology and disease states, enabling human-relevant insights beyond traditional cell culture or animal models. The company also provides drug development tools and instrumentation software to support research and development workflows for researchers across biotechnology, pharmaceutical, consumer health, cosmetics, chemical, food, and agrochemical sectors, as well as government agencies and academic institutions. Founded in 2013 and headquartered in Boston, Emulate aims to accelerate understanding of human biology and improve human health outcomes.
Chunyu Yisheng
Venture Round in 2024
Chunyu Yisheng, established in 2011 and headquartered in Beijing, is a mobile application designed to enhance communication between physicians and patients. The app allows doctors to access their patients' medical records and facilitates direct interaction, enabling patients to schedule appointments and communicate with their healthcare providers. Additionally, Chunyu Yisheng offers reservation line treatment services, further supporting users in managing their health. The company focuses on leveraging Internet technology to improve health outcomes and streamline the healthcare experience.
Zhipu AI is a technology company specializing in developing large-scale artificial intelligence models. It offers API services powered by its General Language Model (GLM) series, designed to handle both Chinese and English tasks. The company's products include chatbots and advanced AI tools, aiming to reduce manual labor in digital tasks.
Shengshu Technology
Seed Round in 2024
Shengshu Technology specializes in developing generative AI infrastructure for multi-modal large-scale models. It integrates text, images, videos, 3D data, and other modalities to create innovative AI solutions.
Pinnacle Medicines
Series A in 2024
Pinnacle Medicines is a biotechnology company based in Doylestown, Pennsylvania. It specializes in peptide drug discovery, utilizing AI-based tools to develop safe and effective therapeutics for unmet medical needs.
DH-Robotics
Series C in 2024
DH Robotics Technology Co., Ltd., founded in 2016 and based in China, specializes in the research and development of robotic hands and industrial robots. The company focuses on creating electric gripping jaws intended to enhance intelligent manufacturing processes. Its products are designed to be stable, secure, and easily integrated, catering to the needs of advanced manufacturing and lean production. By developing cost-effective solutions, DH Robotics aims to support flexible and intelligent demands within the manufacturing sector.
Alamar Biosciences
Series C in 2024
Alamar Biosciences, founded in 2018 and headquartered in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that facilitates protein analysis and the creation of antibody technologies. This platform is designed to enhance the diagnosis of diseases, particularly cancer, while also supporting the discovery of new biomarkers. By enabling healthcare providers to detect diseases at an early stage, Alamar Biosciences aims to improve patient outcomes through timely interventions and potential cures.
Dr.Clear Aligner
Series F in 2024
Dr.Clear is an oral invisible orthodontic solution service provider that specializes in offering safe and comfortable digital solutions for face development management and invisible dental correction for children and adolescents.
Hope Medicine
Series B in 2024
Hope Medicine is a biopharmaceutical company focused on researching, developing, and commercializing innovative drugs to enhance the quality of life for various common male and female diseases. The company specializes in translational medicine and aims to address significant health challenges by leveraging global research initiatives. Hope Medicine is engaged in the development of monoclonal antibodies, protein-based therapies, and other drug formulations targeting endocrine, cardiovascular, and metabolic diseases. Through its efforts, the company seeks to provide underserved patient populations with access to effective and affordable treatments, ultimately improving their health outcomes.
Jasper Therapeutics
Post in 2024
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, that specializes in developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. Founded in 2018, the company aims to enhance the safety and efficacy of conditioning agents to broaden the application of curative therapies. Jasper's lead product, JSP191, is a humanized monoclonal antibody currently in clinical development, designed to act as a conditioning agent by selectively clearing hematopoietic stem cells from bone marrow in patients undergoing stem cell transplants. The company also utilizes an engineered hematopoietic stem cells platform to address the limitations of transplant grafts, thereby increasing the accessibility of both allogeneic and autologous gene-edited hematopoietic stem cell therapies for a larger patient population.
Silicon Yi Technology
Venture Round in 2024
Silicon Yi Technology is a biotech firm specializing in RNA nanopesticide research and development designed to target pests and diseases.
Ruining Bio
Series B in 2024
Ruining Bio provides clinical medical solutions such as tumor radiotherapy protection, wound repair, tumor embolization, and anti-tumor drugs. Ruining Bio brings together various professionals in materials, chemistry, biomedical engineering, and clinical medicine.
Magair Chemical
Series A in 2024
Magair Chemical is a chemical synthesis CRO that was founded by Magera Technology. It is committed to using automated and intelligent platforms to provide new drug R&D customers with a new generation of chemical synthesis CRO services, significantly shortening the delivery of chemical synthesis links in the new drug R&D cycle, and significantly reducing the costs associated with chemical synthesis, removing pharmaceutical synthesis's current reliance on manual operations.
Suzhou Supermag Intelligent Technology Co., Ltd. (hereinafter referred to as Suci Technology) is committed to the research and development, production and sales of maglev high-speed motors. With the design authorization of magnetic levitation compressors, magnetic levitation blowers, magnetic levitation pumps, etc., it provides core components such as magnetic levitation motors, magnetic levitation bearings, magnetic levitation controllers, and displacement sensors.
DeBank offers a cryptocurrency wallet that enables users to track their decentralized finance (DeFi) investments across multiple blockchains. It supports over 800 DeFi protocols, allowing users to monitor deposits, earned interest, and perform token swaps.
Xiaoe Tech
Series D in 2024
Xiaoe Tech is a technology service provider that specializes in new education, offering a variety of software solutions and services tailored for different industries. The company develops SaaS tools for knowledge payment, including enterprise training, cloud services, and content distribution. Its offerings support content entrepreneurs and educational institutions by providing essential resources such as data, traffic management, and consulting. Xiaoe Tech's products facilitate brand communication, traffic growth, classroom management, and student engagement, ultimately enabling a streamlined approach to business monetization in the education sector. By focusing on both tools and strategic support, Xiaoe Tech helps clients build and manage their online knowledge dissemination platforms effectively.
PRCXI Biotechnology
Seed Round in 2024
PRCXI Biotechnology is a biotech company that provides bioinformatics and automation solutions for life science and the manufacturing of analytical instruments.
Swap is a company that makes a battery interchange system that is designed to replace the traditional charging process for electric motors. The company offers an energy switching system comprised of both energy stations and handmade batteries that can be used with the assistance of a mobile application, allowing users to supply speed and timeliness to bike riders at a low cost. The company aims to support the nation's zero-emission goal by providing the revolutionized charging infrastructure
ACXEL Tech specializes in developing advanced large-area electronics that enable innovative applications in drug discovery and biological research. The company's proprietary digital microfluidic platform utilizes millions of 'active' pixels to manipulate liquid droplets with high precision and speed. This technology serves as a programmable and cost-effective solution for various applications, including fundamental bio-related research, cell line development, cell therapy, synthetic biology, and antibody therapy. By allowing clients to conduct complex experimental procedures at the single-cell level, ACXEL enhances productivity and efficiency within the fields of chemistry, biology, and medtech.
Leapstack
Series C in 2023
Leapstack is an insurance technology company founded in February 2016 and headquartered in Shanghai, with additional offices in Beijing and Nanjing. The company specializes in big data artificial intelligence solutions tailored for commercial insurance providers and social security management agencies. Leapstack develops a data analysis and management platform that enhances the insurance claims process by offering services such as risk control monitoring, post-medical reimbursement, and anti-fraud compliance identification. By addressing inefficiencies within the insurance industry, Leapstack aims to improve operational effectiveness and facilitate better decision-making for its clients.
Yibai Health
Venture Round in 2023
Yibai Health is a clinical research medical group that builds clinical trial centers for hospitals.